Browse by Person

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 16.


Barrow, P, Richman, SD, Wallace, A et al. (8 more authors) (2019) Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial. Histopathology, 75 (2). pp. 236-246. ISSN 0309-0167

Ham-Karim, HA, Ebili, HO, Manger, K et al. (4 more authors) (2019) Targeted Next-Generation Sequencing Validates the Use of Diagnostic Biopsies as a Suitable Alternative to Resection Material for Mutation Screening in Colorectal Cancer. Molecular Diagnosis & Therapy, 23 (3). pp. 383-393. ISSN 1177-1062

Richman, SD, Fairley, J, Hall, JA et al. (5 more authors) (2018) Results of the UK NEQAS for Molecular Genetics reference sample analysis. Journal of Clinical Pathology, 71 (11). pp. 989-994. ISSN 0021-9746

Alderdice, M, Richman, SD, Gollins, S et al. (12 more authors) (2018) Prospective patient stratification into robust cancer‐cell intrinsic subtypes from colorectal cancer biopsies. Journal of Pathology, 245 (1). pp. 19-28. ISSN 0022-3417

Seligmann, JF, Hatch, AJ, Richman, SD et al. (8 more authors) (2018) Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. JAMA Oncology, 4 (4). pp. 564-568. ISSN 2374-2437

Richman, SD, Fairley, J, Butler, R et al. (1 more author) (2017) RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009–2016). Virchows Archiv, 471 (6). pp. 721-729. ISSN 0945-6317

Bosch, LJW, Trooskens, G, Snaebjornsson, P et al. (21 more authors) (2017) Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. Oncotarget, 8 (38). pp. 63140-63154. ISSN 1949-2553

Seligmann, JF, Fisher, D, Smith, CG et al. (9 more authors) (2017) Investigating the poor outcomes of BRAF - mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials. Annals of Oncology, 28 (3). pp. 562-568. ISSN 0923-7534

Richman, SD, Fairley, J, Butler, R et al. (1 more author) (2017) How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation. Journal of Clinical Pathology, 70 (1). pp. 58-62. ISSN 0021-9746

Schoon, J, Brock, IW, Cox, A et al. (7 more authors) (2016) The effect of single nucleotide polymorphisms on clinical outcome and survival in the FOCUS (fluorouracil, oxaliplatin and irinotecan: use and sequencing) clinical trial of metastatic colorectal cancer. Anticancer Research, 36 (12). ABSTR055. pp. 6717-6718. ISSN 0250-7005

Seligmann, JF, Elliott, F, Richman, SD et al. (7 more authors) (2016) Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer. JAMA oncology, 2 (5). pp. 633-642. ISSN 2374-2437

Richman, SD, Southward, K, Chambers, P et al. (16 more authors) (2016) HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: Analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. The Journal of Pathology, 238 (4). pp. 562-570. ISSN 0022-3417

Richman, SD, Adams, R, Quirke, P et al. (10 more authors) (2016) Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. Journal of Clinical Pathology, 69 (1). pp. 35-41. ISSN 0021-9746

Maughan, TS, Meade, AM, Adams, RA et al. (22 more authors) (2014) A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? British Journal of Cancer, 110 (9). 2178 - 2186. ISSN 0007-0920

Proceedings Paper

Richman, SD, Adams, R, Brown, E et al. (14 more authors) (2017) FOCUS4: MAMS Trial Design in Action. Early Closure of FOCUS4-D (Pan-HER 1, 2 and 3 Inhibitor Versus Placebo) in Advanced Colorectal Cancer (aCRC) Patients, with Tumours Wildtype (WT) for KRAS, NRAS, bRAF and PIK3CA. In: Journal of Pathology. Belfast Pathology 2017: 10th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 20-23 Jun 2017, Belfast, Northern Ireland, UK. Wiley , S13-S13.

Richman, SD, Hemmings, GJ, Chambers, P et al. (8 more authors) (2015) Loss of pTEN Expression is Strongly Associated with the Presence of the BRAF V600E Mutation, and Further Complicates Combination Treatment Strategies for Patients with Advanced Colorectal Cancer. In: Journal of Pathology. Dublin Pathology 2015. 8th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 23-25 Jun 2015, Dublin, Ireland. Wiley , S14-S14.

This list was generated on Sun Aug 18 10:31:19 2019 BST.